#Sweden #Lund #Hansa Biopharma #imlifidase #Autoimmune Disease

Hansa Biopharma Achieves Enrollment Milestone in Pivotal Anti-GBM Trial

Hansa Biopharma, a pioneering biopharmaceutical company based in Lund, Sweden, recently announced a significant milestone in its research efforts: the completion of patient enrollment in the GOOD-IDES-02 trial, a global Phase 3 clinical study focusing on the treatment of anti-glomerular basement membrane (anti-GBM) disease. This rare autoimmune disorder, which affects approximately 1.6 individuals per million each year, can have devastating effects on kidney function, leading to severe health complications and even death.

The trial aims to investigate the effectiveness of Hansa's innovative drug, imlifidase, which has already received orphan drug designation from both the U.S. FDA and the European Medicines Agency. Originally, the enrollment was set to conclude in 2025, but Hansa's rapid progress enabled the recruitment of all 50 participants sooner than expected.

Søren Tulstrup, the President and CEO of Hansa Biopharma, expressed satisfaction with the swift enrollment rates, emphasizing the urgency and unmet needs of patients suffering from anti-GBM disease. "The completion of patient enrollment in this pivotal Phase 3 trial marks an important milestone in our efforts to investigate the potential role of imlifidase in addressing the high unmet need in this condition," he remarked. The trial participants comprise individuals who have lost significant kidney function; currently, about two-thirds of them face kidney failure, often requiring long-term dialysis.

GOOD-IDES-02 is being conducted at more than 40 clinical centers across the U.S., U.K., and EU and utilizes an open-label design. The trial further aims to evaluate the combined effectiveness of imlifidase with a standard treatment regimen that includes immunossuppressives, glucocorticoids, and plasma exchange therapy. Of the 50 patients enrolled, half will receive imlifidase in addition to standard care, while the other half will receive only the standard regimen. Researchers will monitor renal function outcomes after six months, using metrics such as estimated glomerular filtration rate (eGFR) and the necessity of dialysis.

Additionally, the trial will also assess the safety profile of imlifidase and its impact on patients' pulmonary symptoms, quality of life, and overall health. The results from this study are expected to be shared in 2025, providing critical insights into the future treatment options for patients with this debilitating autoimmune condition.

Understanding Anti-Glomerular Basement Membrane Disease

Anti-GBM disease, sometimes known as Goodpasture syndrome, is a severe autoimmune disorder where the body mistakenly produces antibodies that attack the glomerular basement membrane in the kidneys. In addition to kidney issues, many patients also face respiratory complications due to lung involvement. Without timely intervention, anti-GBM can lead to severe kidney damage, necessitating dialysis or kidney transplantation. Tragically, in some cases, the disease can be fatal during its acute phase.

The introduction of immunoglobulin G (IgG) antibody-cleaving enzyme therapy, like imlifidase, represents a potential breakthrough in treatment. Imlifidase works by quickly cutting IgG antibodies, effectively disabling their harmful immune response—an approach crucial for patients requiring urgent care. Currently, imlifidase has conditional marketing approval in Europe under the brand name IDEFIRIX® for desensitizing highly sensitized adult kidney transplant candidates.

Hansa Biopharma continues to explore the therapeutic potential of imlifidase not only for anti-GBM disease but also for other autoimmune conditions, including Guillain-Barré syndrome, demonstrating commitment to addressing serious unmet medical needs in transplants and autoimmune therapies.

With successful trial outcomes, Hansa aims to pave the way for new treatment avenues that could vastly improve patient lives, offering hope where current therapies fall short. The progress made in the GOOD-IDES-02 trial underscores Hansa Biopharma's dedication to innovation in rare immunological diseases.

For more information regarding the trial, interested parties can find details at ClinicalTrials.gov under the identifier NCT05679401.

About Hansa Biopharma

Hansa Biopharma is dedicated to developing and commercializing advanced therapies for patients with rare immunological conditions. With its robust IgG-cleaving enzyme technological foundation, the company aims to address significant medical challenges across transplant, autoimmune disease, gene therapy, and cancer landscapes. For more updates, visit Hansa Biopharma's website.